Last reviewed · How we verify
NCT05157932: Talk-Test
An Evaluation of the Talk Test for Exercise Prescription for Home-Based Cardiac Rehabilitation
NA trial testing Talk test prescription in Coronary Artery Disease in 40 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2026
Quick facts
| Lead sponsor | Ottawa Heart Institute Research Corporation |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 8 July 2022 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 July 2026 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Talk test prescription
- CPET prescription
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Ottawa Heart Institute Research Corporation
Who can join
40 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this pilot RCT are to examine if the Talk Test is an effective and safe tool as compared with CPET for exercise prescription in patients who have undergone CABG or PCI and enrolled in a home-based CR program with virtual exercise training monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05157932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Ottawa Heart Institute Research Corporation trials
Trials by the same sponsor.
- NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
- NCT07002450 — Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Departm · NA · recruiting
- NCT06832085 — Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation · Phase 4 · recruiting
- NCT06556667 — MAX - SHOCK Clinical Trial · NA · recruiting
- NCT06816888 — Impact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05157932 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05157932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing